Health Canada has conditionally approved the drug lecanemab for slowing early-stage Alzheimer’s disease, prompting concerns about its efficacy and accessibility in Canada. Lecanemab is a synthetic antibody administered via intravenous infusion, targeting the accumulation of amyloid plaque in the brain, a key feature of Alzheimer’s disease.
While lecanemab does not offer a cure or the ability to reverse the disease or retrieve lost memories, it represents the first disease-modifying Alzheimer’s treatment sanctioned for use in Canada, unlike current medications that focus on symptom management rather than altering the disease’s progression.
The potential effectiveness of the drug and its implications for Canada’s healthcare infrastructure are now critical considerations for individuals with Alzheimer’s, their families, healthcare providers, and governmental bodies.
Eligibility for lecanemab, also known as Leqembi, extends to individuals with mild cognitive impairment and early Alzheimer’s stages. Patients seeking treatment must demonstrate the presence of amyloid plaque in the brain as stipulated by the drug manufacturer. Additionally, patients are required to undergo genetic testing to identify any negative side-effect-associated gene variants, particularly the APOE4 gene variant. The medication is solely available to patients harboring a single or no copy of the APOE4 gene variant, as those with two copies are at a higher risk of experiencing brain swelling or bleeding.
Genetic testing accessibility varies among Canadian provinces and territories, impacting patient eligibility for lecanemab treatment. While the drug heralds a positive milestone in Alzheimer’s treatment, its $26,000 US cost in other nations prompts the need for further research to ascertain its value and noticeable benefits for patients in maintaining independence.
The administration of lecanemab necessitates specialized diagnostics such as lumbar punctures or amyloid PET scans for confirmation of Alzheimer’s diagnosis and eligibility for the medication. Infusions are scheduled every two weeks through an intravenous route, requiring approximately an hour per session. Ongoing monitoring via PET scans or MRIs is imperative to ensure treatment safety and efficacy.
The Canadian Consortium on Neurodegeneration in Aging has outlined potential side-effects, including brain swelling or bleeding observed during clinical trials with lecanemab and other antibody treatments. Dr. Howard Chertkow likened the drug’s impact to a base hit rather than a home run, stressing the importance of identifying patient subgroups that may benefit most from the medication.
Advocacy from the Alzheimer’s Society urges swift action from Canada’s Drug Agency and provincial governments to introduce lecanemab to the market and ensure public funding for widespread patient access, given its substantial cost. While regulatory approval is a significant step, it may take up to two years for new medications to be publicly covered, with private or extended benefits offering potentially earlier access.
